Comparison of four different protocols of I-131 therapy for treating single toxic thyroid nodule.
OBJECTIVE
To compare low and high doses as well as fixed and calculated doses of I-131 in treating toxic thyroid adenoma.


METHODS
In a prospective study, patients with hyperthyroidism and a single hot thyroid nodule and 24-h radioactive iodine uptake of more than 25% were randomly treated with one of four protocols: fixed low dose (FLD, 481 MBq), fixed high dose (FHD, 832 MBq), calculated low dose (CLD, 3.33-3.70 MBq/g), and calculated high dose (CHD, 6.66-7.4 MBq/g). The patients were asked to visit the endocrinologist 2 and 6 months after treatment and every 6 months thereafter. Clinical exam and laboratory tests were done in all patients during each follow-up. A curative effect was considered as absence of thyroid stimulating hormone suppression (thyroid stimulating hormone>0.3). An analysis of variance test was used for comparison of groups.


RESULTS
97 patients completed the follow-up, eight male, 89 female, with a mean age of 43.3 years (SD=13.4) and mean 24-h radioactive iodine uptake values of 48.07% (SD=14.07). No significant difference was noted in the four groups regarding age, sex ratio, thyroid uptake, and thyroid weight. About 10 months after therapy, cure of hyperthyroidism was higher in CHD group compared with other groups. Hypothyroidism was significantly higher in CHD and FHD groups compared with CLD and FLD groups in all follow-ups. No significant difference was noted in the cure of hyperthyroidism between CLD and FLD groups. Mean radioiodine dose administered in calculated groups was significantly less than fixed dose groups.


CONCLUSIONS
CHD protocol is preferable in old patients with toxic adenoma whereas CLD is more appropriate in young patients.
Zakavi
Seyed Rasoul
SR
Mashhad University of Medical Sciences, Mashhad, Iran. srzakavi@yahoo.com
Mousavi
Zohreh
Z
Davachi
Behroze
B
D000328:Adult; D004305:Dose-Response Relationship, Drug; D004307:Dose-Response Relationship, Radiation; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007457:Iodine Radioisotopes / Q000008:administration & dosage*; D008297:Male; D019275:Radiopharmaceuticals / Q000008:administration & dosage; D016606:Thyroid Nodule / Q000175:diagnosis* / Q000532:radiotherapy*; D016896:Treatment Outcome
D007457:Iodine Radioisotopes; D019275:Radiopharmaceuticals